Similar to our results, the combination of sorafenib with STAT3 inhibitors, such as nifuroxazide, has been shown to enhance the cytotoxicity of sorafenib in an HCC xenograft animal model [38]. Here, STAT3 is linked to hepatocellular carcinoma.